Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05718453 |
Other study ID # |
Rasha Abdelfattah |
Secondary ID |
|
Status |
Completed |
Phase |
Phase 1
|
First received |
|
Last updated |
|
Start date |
June 1, 2019 |
Est. completion date |
December 15, 2019 |
Study information
Verified date |
February 2023 |
Source |
Egymedicalpedia |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
COPD is one of the most common causes of health problems worldwide. It is a disease that is
associated with several systemic features that affect its morbidity and mortality.
Description:
The most prominent features of COPD are systemic inflammation and oxidative stress. There is
growing interest in establishing the significance of systemic inflammatory biomarkers in COPD
patients, as they could be useful in evaluating exacerbations, monitoring disease
progression, and evaluating treatment outcomes.
C-reactive protein (CRP) is a biomarker for systemic inflammation, produced mostly by
hepatocytes in response to tissue injury or inflammation.
Tumor necrosis factor - alpha (TNF-α) is a key modulator of the immune system's response to
infection. At the sites of inflammation, this cytokine regulates the function of poly-morphs
and lymphocytes, with essentially protective benefits for the host. Increased TNF-α
production may enhance an injury process locally and also elevated circulating levels may
have negative systemic consequences.
Trace elements are hypothesized to play a role in the pathogenesis of many diseases, either
directly or indirectly. Trace elements play an important function in the inhibition and
activation of enzyme processes .
Zinc, for example, is a co-factor for various enzymes and is important for cell membrane
stability, protein synthesis, proper tissue growth, and nucleic acid metabolism.
Severity of COPD exacerbation is associated with increased levels of copper (Cu) and zinc
(Zn).
Patients with COPD are liable for various electrolyte derangements, especially during
exacerbations. Hyponatremia is typically observed in the final stages of COPD. Hypokalemia
may also occur independently or concomitantly with hyponatremia, and because magnesium plays
a role in muscle tone, a drop in magnesium levels in COPD is a component that reduces
respiratory muscle function and causes muscle fatigue.